Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Assets (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Current Assets for 7 consecutive years, with $1.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 44.47% to $1.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 billion, a 44.47% increase, with the full-year FY2025 number at $1.3 billion, up 44.47% from a year prior.
  • Current Assets was $1.3 billion for Q4 2025 at Beam Therapeutics, up from $1.1 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.3 billion in Q4 2021 to a low of $514.6 million in Q1 2021.
  • A 5-year average of $1.1 billion and a median of $1.1 billion in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 351.07% in 2021, then fell 27.49% in 2024.
  • Beam Therapeutics' Current Assets stood at $1.3 billion in 2021, then decreased by 14.15% to $1.1 billion in 2022, then increased by 10.81% to $1.2 billion in 2023, then dropped by 27.49% to $878.1 million in 2024, then surged by 44.47% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Current Assets are $1.3 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.2 billion (Q2 2025).